Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD

• Published in: Pulmonary pharmacology & therapeutics Vol. 26; no. 2; pp. 256 - 264
• Main Authors: Kempsford, Rodger, Norris, Virginia, Siederer, Sarah
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2013
• Subjects: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists - therapeutic use; Adult; Aged; Asthma; Asthma - drug therapy; Asthma - physiopathology; Benzyl Alcohols - adverse effects; Benzyl Alcohols - therapeutic use; Blood Glucose - analysis; Bronchodilator Agents - therapeutic use; Chlorobenzenes - adverse effects; Chlorobenzenes - therapeutic use; COPD; Electrocardiography; Female; Forced Expiratory Volume - drug effects; Heart Rate - drug effects; Humans; Male; Medical Education; Middle Aged; Pharmacodynamics; Pharmacokinetics; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - physiopathology; Pulmonary/Respiratory; Vilanterol; β2-agonist; Vilanterol; Pharmacodynamics; Pharmacokinetics; β2-agonist; COPD; Asthma

Vilanterol (VI; GW642444M) is a novel inhaled long-acting β2-agonist with inherent 24 h activity in vitro in development as a combination with the inhaled corticosteroid fluticasone furoate for both COPD and asthma. These studies were conducted to determine the safety, tolerability, pharmacodynamics...